AttributesValues
type
value
  • BACKGROUND: : Treatment decisions in patients with multiple sclerosis (MS) during the coronavirus disease 2019 (COVID-19) pandemic are challenging. It is not known whether and how various disease modifying therapies, especially immunosuppressive drugs, affect COVID-19 risk and disease course. METHODS: : Case report RESULTS: : We report a fingolimod-treated MS patient who developed severe COVID-19 but recovered after treatment with tocilizumab. CONCLUSION: : This report suggests that a brief course of tocilizumab for the treatment of severe COVID-19 may be effective while not aggravating pre-existing MS.
Subject
  • Multiple sclerosis
  • Zoonoses
  • Viral respiratory tract infections
  • COVID-19
  • Epstein–Barr virus-associated diseases
  • Ailments of unknown cause
  • Immunosuppressants
  • Occupational safety and health
  • RTT(full)
  • RTTNEURO
part of
is abstract of
is hasSource of
Faceted Search & Find service v1.13.91 as of Mar 24 2020


Alternative Linked Data Documents: Sponger | ODE     Content Formats:       RDF       ODATA       Microdata      About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data]
OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software